Alexza Pharmaceuticals, Inc.and Grupo Ferrer Internacional, S.A.,announced that the European Commission has granted marketing authorization for Adasuve (Staccato loxapine). In...
The FDA Psychopharmacologic Advisory Committee voted 9-8 to recommend Adasuve (inhaled loxapine) from Alexza Pharma, to treat agitation associated with...
Alexza Pharmaceuticals, Inc. and Grupo Ferrer Internacional, S.A., have announced that the Committee for Medicinal Products for Human Use (CHMP)...
Alexza Pharmaceuticals, Inc. announced that they have entered into an exclusive U.S. license and supply agreement with Teva Pharmaceutical Industries...
Alexza Pharmaceuticals announced that it has received a Complete Response Letter(CRL) from the FDA regarding its New Drug Application (NDA)...
This medicinal product is for diagnostic use only. Calculation of a therapeutic [ 131 I]iobenguane dose from a prior tracer-dose. The sensitivity to diagnostic visualisation, and therefore also to therapeutic efficacy, is different for the listed pathologic entities. Pheochromocytomas and neuro-blastomas are sensitive in approximately 90% of patients, carcinoids in 70% and medullary carcinomas of the thyroid gland (MCT) in only 35%.
Radiation therapy of tumour-tissue that is capable of retaining iobenguane. These are tumours arising from cells originating embryologically from the neural crest; pheochromocytomas, neuro-blastomas, carcinoids and medullary carcinomas of the thyroid gland (MCT).